Programme - Life Science 2.0

Stockholm Life Science Conference 2022 - Life Science 2.0

Monday, 28 November 2022

The conference addresses the need to reframe Life Science in the wake of COVID-19 and safeguard life: long-term and globally. Please, visit the conference site for more information.

Monday, 28 November

Registration and coffee.

Welcome and Introduction.
Nina Rawal, Moderator, Partner and Co-Head, Trill Impact Ventures and Ole Petter Ottersen, President of Karolinska Institutet.

Sweden´s Life Strategy – Reframing Life Science.
Karl-Petter Thorwaldsson, Swedish Minister for Business, Industry, and Innovation.

Keynote 1: Building back better: Perspectives of big pharma - The development of COVID-19 vaccines and oral treatment: Experiences from the pandemic.
Mikael Dolsten, Chief Scientific Officer Pfizer.

Keynote 2: Building back better: Perspectives from basic and translational research - How decades of basic research paved the way for new vaccines. 
Uğur Şahin, CEO BioNTech.

Keynote 3: Building back better: The global perspective - Addressing global inequities and production gaps for vaccines and medicines.
Agnes Binagwaho, Vice Chancellor of the University of Global Health Equity, Rwanda.


Panel 1: Life science after COVID-19: Preserving an effective modus operandi while joining forces for universal preparedness and sustainability.

  • Uğur Şahin, CEO Biontech.
  • Mikael Dolsten, CSO Pfizer.
  • Agnes Binagwaho, Vice Chancellor of the University of Global Health Equity in Rwanda.
  • Anders Nordström, Ambassador for Global Health, Swedish Ministry of Foreign Affairs.
  • Juan Pablo Uribe, Global Director Health, Nutrition & Population and the Global Financing, World Bank.
  • Anna Mia Ekström, Professor, Dept of Global Public Health, Karolinska Institutet.
  • Jerome Kim, MD and Director General, International Vaccine Institute, IVI.

Coffee break

Keynote 4: Building a sustainable life science sector - Safeguarding planetary health in the context of UN's Agenda 2030.
Leif Johansson, Chairman of Astra Zeneca, introduced by Professor Annika Östman Wernerson, Karolinska Institutet.

Panel 2: Precision medicine & New Generation - Clinical bringing clinical trials to a new level and accelerating the development treatment and prevention of neglected diseases.

  • Michael Makanga, Executive Director, EDCTP (European & Developing Countries Clinical Trials Partnerships).
  • Janne Lehtiö Professor at Dept. of Oncology and Pathology at Karolinska Institutet and Scientific director of SciLifeLab.
  • Anna Martling, Professor of Surgery at Karolinska Institutet, Chief physician and colorectal surgeon in Tema Cancer, Karolinska University Hospital.
  • Peter Asplund, Governmental Investigator, Improved conditions for Clinical Trials in Sweden
  • Stephan Mielke, Professor of Haematology and Cell Therapy, Karolinska Institutet and Director of Centre for Allogenic Stem Cell Transplantation (CAST) at Karolinska University Hospital.
  • Eleni Aklillu, Professor of Tropical Pharmacology, Karolinska Institute.

Panel 3: Quo vadis? – A global perspective on the future of Life Science Sweden and Stockholm Region have high ambitions for the life science sector. How should we combine the ambition to be among the best IN the world to be best FOR the world?  

  • Jenni Nordborg, Head of the Office for Life Sciences, Swedish Government Offices
  • Irene Svenonius, Regional Chair for Finance
  • Jan Larsson, President and CEO Business Sweden
  • Helena Strigård, CEO/Director-General at Sweden Bio
  • Anders Blanck, Managing Director of LIF
  • Ketil F. Widerberg, General Manager of Oslo Cancer Cluster and Board Member of KI Holding AB

Wrapping up: The role and responsibility of academia in implementing Life Science 2.0

  • Ole Petter Ottersen, President of Karolinska Institutet and Olli Kallioniemi, Director of SciLifeLab together with representatives of universities in the Stockholm Region.

Networking Luncheon